Amyloidosis Foundation Announces 2022 Research Grant Recipients

Amyloidosis Foundation Announces 2022 Research Grant Recipients

We are pleased to announce the funding of three new Junior Investigator Research Grants for 2022. The Amyloidosis Foundation Research Grants have been awarded to the following applicants:

Sébastien Bender, PhD of the University of Limoges in France.  His study is titled “Mouse model of AL amyloidosis: toward a better understanding of the disease”.

Zainul S. Hasanali, MD, PhD of University of Pennsylvania, PA.  His study is “Targeting amyloidosis through study of calcium dependent endoplasmic reticulum resident protein folding chaperones and their effect on antibody production in plasma cells”.  

Taxiarchis Kourelis, MD of Mayo Clinic, Rochester, MN. His research is titled “Characterizing the role of the tissue immunome in the pathogenesis of renal AL amyloidosis”.

The Amyloidosis Foundation has awarded over $2 million to research since the inception of the grant program in 2005.

Click here for photos and to read more about their proposals.

Congratulations!


2021 Giving Tuesday

2021 Giving Tuesday

On November 30, 2021, people all around the world are coming together to tap into the power of human connection and strengthen communities and change our world. Will you be one of them? 

Amyloidosis Foundation will be participating in GivingTuesday and we need your help! 

By joining the GivingTuesday movement, you’re proving that in times of uncertainty, generosity can bring the whole world together. 

Here is how you can get ready to give:

  1. Mark your calendar 
  2. Give. On November 30, go to our donation link and give.
  3. Spread the word. Encourage your friends and family to join you in creating real impact on November 30 by sharing what our mission means to you and why you support our organization. Make sure to use hashtag #GivingTuesday and tag us so we can share!

Let’s rally together to build stronger communities. 

The Amyloidosis Foundation is a non-profit organization that supports research through our annual grant program. Our mission is to raise awareness of the disease within the medical community and the public, in addition to providing education, information, and support for patients and their families. 

In 2020, we raised over $15,000. This year our goal is $20,000 and we need your help!

Those who are interested in joining Amyloidosis Foundation’s #GivingTuesday initiative can click here.

Together we give. Share your #UNSELFIE. Use our template and share it on Facebook, Instagram, and Twitter.



Fall Webinar Recording: Established and Emerging Treatment Strategies for AL Amyloidosis in 2021

Fall Webinar Recording: Established and Emerging Treatment Strategies for AL Amyloidosis in 2021

Listen to our latest webinar that was recorded on September 14, 2021. Presented by Heather Landau, MD who is a hematologist-oncologist and the Director of the Amyloid Program at Memorial Sloan Kettering (MSK) Cancer Center focused on increasing access to novel, effective therapies in AL amyloidosis and has investigated drugs at all stages of development.  She has conducted multiple investigator-initiated clinical trials exploring novel agents and approaches, including consolidation and maintenance strategies in high-risk patients.  She led the development of MSK’s Outpatient Transplant Service and is studying innovative ways to optimize high-dose therapy and transplant care.

LISTEN HERE



Webinar: “Established and Emerging Treatment Strategies for AL Amyloidosis in 2021

Webinar: “Established and Emerging Treatment Strategies for AL Amyloidosis in 2021

Fall 2021 Live Webinar Event

Please join us for our webinar event presented by Dr. Heather Landau.

View Webinar Here

Heather Landau, MD, is a hematologist-oncologist and the Director of the Amyloid Program at Memorial Sloan Kettering (MSK) Cancer Center focused on increasing access to novel, effective therapies in AL amyloidosis and has investigated drugs at all stages of development. She has conducted multiple investigator-initiated clinical trials exploring novel agents and approaches, including consolidation and maintenance strategies in high-risk patients.  She led the development of MSK’s Outpatient Transplant Service and is studying innovative ways to optimize high-dose therapy and transplant care. Pharmacokinetically dosed conditioning has the potential to truly personalize high-dose therapy and Dr. Landau has shown that delivering transplant care at home is safe and improves the quality of life and satisfaction of patients and caregivers. As an active member of the Amyloid Research Consortium (ARC), Dr. Landau has worked with the FDA to identify scientifically rigorous but feasible clinical trials designs and incorporate clinically meaningful endpoints to accelerate drug approval in this disease. Translational research efforts focus on using genomic approaches to understand the biology of pathologic plasma cells in AL amyloidosis, including their sensitivity and resistance to therapies. Partnering with colleagues in pathology and clinical laboratory medicine, Dr. Landau is developing more sensitive methods of detecting and monitoring monoclonal disease using mass spectrometry. As a member of the International Society of Amyloidosis, she has contributed to recently developed clinical guidelines that highlight best practices for hematopoietic cell transplantation. She is a member of the International Myeloma Society and International Kidney Monoclonal Gammopathy Working Group. Dr. Landau’s expertise in the field of amyloidosis leads to frequent invitations to lecture nationally and internationally. She also participates regularly in patient-centered initiatives through the Amyloidosis Research Consortium, Amyloid Foundation, Patient Support Groups and serves as an advisor to Mackenzie’s Mission.


3RD European ATTR Amyloidosis Meeting for Patients and Doctors

3RD European ATTR Amyloidosis Meeting for Patients and Doctors

The 3rd European ATTR Amyloidosis meeting will be hosted 100% virtually on September 6-8, 2021. There will be 2 Channels, one dedicated to doctors and one dedicated to patients, across 3 days delivering a packed and high-quality scientific programme including cutting-edge lectures by international leaders in their field, sessions in collaboration with partnering companies, poster sessions, and much more. It’s the perfect place to keep you updated about ATTR amyloidosis!

Registration is open! You can now book your virtual seat!
 Register now

Submission is open! Be part of the programme by submitting an abstract
before July 18, 2021.
 Submit here

Spring Webinar Recording: Emerging treatment landscape for Cardiac Amyloidosis

Spring Webinar Recording: Emerging treatment landscape for Cardiac Amyloidosis

Listen to this informative webinar that was recorded on May 26, 2021on the Emerging treatment landscape for Cardiac Amyloidosis. The webinar was hosted by Mathew S. Maurer, MD a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation.  He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). Dr. Maurer is a member of the Advanced Cardiac Care Center at New York Presbyterian Hospital – Columbia Campus. 

After the presentation, Dr. Maurer answered many interesting questions from patients, physicians and family members.

Please share this link with your family and friends to spread amyloidosis awareness.

LISTEN HERE


Webinar: “Emerging treatment landscape for Cardiac Amyloidosis”

Webinar: “Emerging treatment landscape for Cardiac Amyloidosis”

Live Webinar Event

Emerging treatment landscape for Cardiac Amyloidosis

Dr. Mathew S. Maurer, MD

Dr. Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation.  He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). Dr. Maurer is a member of the Advanced Cardiac Care Center at New York-Presbyterian Hospital – Columbia Campus

  • When: May 26, 2021
  • Time: 3:00 pm EDT

View Webinar Here


2nd Annual “Run for Your Life” Virtual Run

2nd Annual “Run for Your Life” Virtual Run
WHAT IS A VIRTUAL RUN?

A virtual run is a run that can be run (walked or rolled) from any location you choose. You can run, jog, or walk on the road, on the trail, on the treadmill, at the gym, or on the track. You get to run your own race, at your own pace, and time it yourself. 

Sign Up for the “Run for Your Life” Virtual Run

Registration for the Virtual Run is currently open.

  • 5K Run – $25.00
  • 10K Run – $35.00

Register Here

Or call the office to register at 248-922-9610.

Once you have signed up for the run, either a 5K or 10K, then decide on the course you want to do, or you can do it on the treadmill. You time yourself. You can even get your friends and/or your kids to run with you too. The run should be completed between May 1, 2021, and July 31, 2021.

Don’t forget to share the run with your friends and family!

Take Photos and Share Your Run with Us

Once you have completed your run, send us some photos to share with kathi@amyloidosis.org.

We would love to hear about your run! Join our Amyloidosis Facebook page and Instagram page. #AFVirtualRun #AFVirtualRun2021 #VirtualRun2021 #RunforyourLife2021